Archive for the ‘Treatment’ Category

Living Well When You Don’t Feel Well: Overcoming Lyme Disease & Illness

http://  Approx. 18 Min

Living Well When You Don’t Feel Well

Overcoming Lyme Disease & Illness

Joe Trunzo PhD Professor of Psychology

Dr. Trunzo highlights a different way of thinking and coping with diseases (and life), specifically Lyme disease. 

He earned his undergraduate degree in 1993 from Marywood University in Scranton PA and completed his graduate work in 2000 at Drexel University in Philadelphia, PA. He completed his pre-doctoral internship at the University of Vermont and his post-doctoral fellowship at the Centers for Behavioral & Preventive Medicine at Brown University Medical School in Providence, RI. He is a Professor of Psychology and Chair of the Department of Applied Psychology at Bryant University. He is also a licensed, practicing clinical psychologist with expertise in the psychological management of chronic medical illnesses such as cancer and Lyme disease, as well as the treatment of mood and anxiety disorders, especially obsessive compulsive disorder. He serves on several professional committees and belongs to a number of professional organizations. In his spare time, he enjoys being with his family, live music, running, and mountain climbing.

This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx

_______________

**Comment**

A very sane and logical talk on the Lyme/MSIDS controversy involving three camps of thought, which then moves on into how to develop a mindset that focuses on living the best life you can while sick.  Dr. Trunzo utilizes the mindfulness based, values-oriented behavioral therapy called ACT (Acceptance & Commitment Therapy) to help patients.

He states that by not accepting what patients are feeling and going through, they can trap themselves and create more problems.  I must throw in a personal note here: one of the most helpful things I was ever told early on by another patient who reached the other side was:

“Don’t be depressed about feeling depressed.”

This may be laughingly simple; however, I found that I needed to give myself permission to feel depressed.  Knowing, understanding and accepting the fact I was going to feel miserable and have some really rotten days (or months!) helped me tremendously.  Being chronically/persistently infected with multiple pathogens that work symbiotically and that are in your brain and virtually every organ of your body wreaking havoc, not only affects you physically but emotionally and spiritually.  Add in the fact that mainstream medicine denies this fact entirely and that your friends and family may choose to believe you are a hypochondriac rather than an extremely ill person who needs help, because after-all you “look fine” – and you can become very depressed and isolated indeed, which doesn’t help the healing process at all!

Obviously, the goal here is not to remain sick, but to achieve wellness and health; however, with Lyme/MSIDS that may take years to accomplish, and even then there is a very real potential that facets of your health may never return to the way they were before you became infected.  As with all things in Lymeland, everyone’s journey is unique to them and no two cases look alike.

For more:

First Case Report of Pancreatitis in Lyme Disease

https://researchopenworld.com/first-case-report-of-pancreatitis-in-lyme-disease/

First Case Report of Pancreatitis in Lyme Disease

Publication history

Received: November 14, 2019
Accepted: November 21, 2019
Published: November 25, 2019

Citation

A Baisse, S Parreau, A Abdeh, N Pichon (2019) First Case Report of Pancreatitis in Lyme disease. Internal Med Res Open J Volume 4 (2): 1–2. DOI: 10.31038/IMROJ.2019423

Short Abstract

We report a case of Lyme disease, revealed by pancreatic damage in a 49-year-old man without any medical history. The Lyme disease was revealed by repeated abdominal pain for 4 weeks, a skin lesion of quadricipital region, biological and radiological results showing pancreatic abnormalities.

Case Report

A 49-year-old man, non-alcoholic forest worker, with no past medical history, consulted to the Emergency Department for fever and persistent abdominal pain for a week. The biological results including, C – reactive protein (CRP), lipase, hepatic assessment were normal as well as contrast-enhanced abdominal Computed Tomography (CT). On the day after, the evolution was favorable under symptomatic treatment including nefopam and paracetamol and the patient was discharged from the hospital. One week later, the patient was admitted to the Emergency Department with an identical symptomatology. A posterior quadricipital peeling skin lesion, appeared two weeks earlier according to the patient, was observed (Figure 1a.) A gastroscopy, a colonoscopy, other abdominal CT and biological tests were performed. An inflammation biomarker elevation was observed (CRP: 180 mg/L and hyperleukocytosis: 13.3 G/L) without other biological abnormalities (lipase: 48 UI/L, ALAT: 48 UI/L). The endoscopic examinations and abdominal CT were normal. The patient was discharged from the hospital without any treatment. Half a month later, the patient was admitted to the Emergency Department for the third time and recurrence of the abdominal pain. The clinical examination found a hemodynamic stability, an abdominal pain of the left hypochondrium associated with a cutaneous ulcerative and non-progressive skin lesion in the same region as previously mentioned (Figure 1b.). The biological assessment found a very mild inflammatory syndrome (CRP 86 mg/L, Procalcitonin < 0.2 ng/mL, leukocytes 9.5 G/L), a high lipase level at 1714 IU/L without hepatocellular abnormalities. The third abdominal CT revealed an aspect of pancreatic necrosis with a pseudocyst (6 cm) at the tail of the pancreas, in contact with the splenic hile and the posterior wall of the stomach (Figure 1c.). The patient was hospitalized in Intensive Care Department with the diagnosis of pancreatitis.

On admission, the work-ups looking for the usual causes of pancreatitis (alcohol, gallstones, medications induced, hypercalcemia, traumatic, chemical exposures, hereditary diseases, infections) were negative. Regarding the skin patient’s lesion and anamnesis, the diagnosis of Lyme disease was evoked. His Lyme serology was strongly IgM positive and confirmed by Western Blot. He was treated with ceftriaxone associated with effective analgesic therapy. The clinical and biological course was uneventful and the patient was discharged from the hospital after 3 weeks. The relationship between Lyme disease and acute pancreatitis was strongly suspected.

Discussion

Lyme disease is an endemic zoonosis, transmitted to humans by a tick bite causing a multisystemic impairment due to a Gram-negative bacillus, Borrellia burgdorferi [1]. The disease schematically includes two phases and a polymorphism in clinical manifestations: a primary phase with chronical migrans erythema and articular signs (80% of cases), a secondary phase of heterogeneous and lymphatic dissemination, inaugurated by flu-like symptoms and associating neurological, cardiac or articular signs that could become chronic [2]. Each of these attacks could be inaugural or/and isolated [3]. Concerning the anamnesis, only 30% of patients remember a tick bite [4].

The heterogeneity of presentation in Lyme disease includes the serodiagnosis as a central investigation for confirmation [5]. Hepatic impairment due to Lyme disease, including hepatitis and hepatomegaly, is inconsistent, commonly found in early stage but often asymptomatic and with plasmatic manifestations [6]. A moderate hypertransaminasemia (2 to 3 N) could be noted, predominating on the ALAT. This hepatic biologic involvement is present in 27 to 66% of cases [7]. This can be explained by a systemic, lymphatic migration of the incriminated bacteria and a secondary hepatic sequestration [8]. To our knowledge, this physiopathological evolution to explain liver disorders has never been described for pancreas but is probably similar.

Regarding the treatment of Lyme disease, the cycline are recommended for the uncomplicated forms. An antibiotic treatment with cephalosporins could be considered for cardiac, neurological or complicated cases [2]. The evolution is favorable in 85% of patients, including hepatic acute injuries [9].

In our case, the skin lesion associated with a supposed tick bite, the anamnesis, the absence of other cause of pancreatitis, the favorable evolution under antibiotic treatment and especially the strong positivity of the serology are in favor of a Borrelia burgdoferi infection.

Conclusion

The authors report the first case of pancreatitis revealing a Lyme disease. Clinical, biological and evolutionary findings support the responsibility of Lyme disease in the pathogenesis of our pancreatitis case.  (See link for article and pictures)

_________________

**Comment**

How many patients have had this or similar issues but didn’t have the rash, had negative serology and didn’t fit the other arbitrary standards that mainstream medicine has imposed that thousands of other patients don’t fit?  God only knows.

Research Suggests Cancer Medication Could Help Fight Lyme Disease

https://www.wamc.org/news/2023-08-08/research-suggests-cancer-medication-could-help-fight-lyme-disease

Research suggests cancer medication could help fight Lyme Disease

U.S. Dept. Of Agriculture

Research out of UMass Amherst suggests medication used to stop the spread of cancer may help fight tick-borne illnesses such as Lyme Disease. WAMC’s Jim Levulis spoke with Stephen Rich, the executive director of the New England Regional Center of Vector-borne Diseases, about the study and how it relates to existing Lyme treatments.

Rich: Generally that’s antibiotic treatments, most often doxycycline. A reasonable course of doxycycline takes care of most early detected Lyme disease cases. There other antibiotics where doxycycline is contraindicated, there are other antibiotics that work as well. Things like amoxicillin, but basically antibiotics.

(See link for article and interview)

_________________

SUMMARY:

  • Lyme spirochetes have a dependency upon a particular pathway called glycolysis which is dependent upon lactate dehydrogenase or LDH.
  • Certain cancer cells are similarly constrained in their metabolic profiles.
  • Inhibitors of the LDH molecule have been used to treat cancerous tumors.
  • The inhibitors, when tested in the test tube against Lyme spirochetes didn’t eliminate the borrelia, but they stopped it from growing (bacteriostatic).
  • They are now going to test this in lab animals and then companion animals or people.
  • Despite it being a wet, warm July in Massachusetts, there were lots of ticks at work.

For more on Lyme treatments utilized by experienced Lyme literate doctors (LLMDs) go here.

I must add that this proves ticks are ecoadaptive and tick and disease proliferation has nothing to do with the weather or supposed ‘climate change,’ which is simply a propaganda narrative touted by climate scientists who are on a “gravy train” to secure funding via government grants.

Expert after expert has stated “there is no climate emergency.”

Further, ‘the powers that be’ are using the climate agenda to desperately push a much bigger diabolical plan:  UN’s  Our Common Agenda platform, the WHO’s Pandemic Treaty, and the WEF’s depopulation, massive surveillance, and censorship designs which will give unelected officials unlimited power with ZERO oversight.

Do not fall for the unscientific clap-trap of ‘climate change.’  It’s part of an evil dystopian plan.

Kris Kristofferson “…As Sharp As He’s Been in the Past 20 Years Because of His Treatments”

https://www.survivornet.com/articles/country-singer-songwriter-kris-kristofferson-lyme-disease-alzeimers/

Country Singer-Songwriter Kris Kristofferson, 87, Had Symptoms Misdiagnosed As Alzheimer’s But It Turned Out To Be Lyme Disease

Danielle Cinone
8/2/23

ACTION ALERT: FDA Trying to Ban CBD

https://www.paintreatmentdirectory.com/posts/the-fda-is-trying-to-ban-cbd-supplements

The FDA is Trying to Ban CBD Supplements


The FDA is Trying to Ban CBD Supplements


Editor’s note: The following article and call to action about the FDA’s efforts to ban CBD supplements is being reprinted from the Alliance for Natural Health website. This is not the first time the FDA has tried banning natural treatments relied on by millions of Americans, but part of a long and corrupt history. The FDA has also been trying for several years to ban kratom, an herb being successfully used by millions of Americans to treat pain, opioid addiction and withdrawal, anxiety and more. Recently, the FDA has also taken action against homeopathy, a safe, natural system of medicine used worldwide since its development in 1810. The FDA has been trying to get stronger regulatory authority to take vitamins and other supplements off the market. It seems the FDA is leaving no stone unturned in its efforts to protect the profits of the pharmaceutical industry instead of protecting the health of the public.

The FDA Misleads on CBD Safety

…providing further evidence that the agency is trying to engineer a ban on affordable CBD to protect drug industry profits. Action Alert!

As the evidence of CBD’s myriad health benefits continues to pile up, it increasingly looks to us like the FDA is preparing to issue a ban on CBD supplements. We must support bills in Congress that take the issue out of the FDA’s hands by allowing the sale of CBD in supplement form.

Lawmakers do appear to be taking this issue seriously. In addition to the bill introduced by Representative Morgan Griffith (R-VA), another similar bill has just been introduced by Senators Ron Wyden (D-OR), Rand Paul (R-KY), Jeff Merkley (D-OR), and Representative Earl Blumenauer (D-OR) to allow the sale of CBD in supplements. Additionally, Congress is holding a hearing on July 27 during which members will formally scrutinize the impact of the FDA’s failure to develop a regulatory pathway for the sale of CBD in supplements and food. Let’s show the FDA the scale of our opposition to its unjustified plan and demonstrate the huge level of grassroots support for CBD supplements ahead of the hearing.

We want to make it crystal clear what we face if we don’t stop the FDA in its tracks. CBD, or cannabidiol, is one of over 100 natural compounds called cannabinoids found in a wide range of plants, most notably the hemp plant. The cells of our bodies are laced with cannabinoid receptors that form part of the endocannabinoid system that is essential to life and to robust health. We produce cannabinoids internally (endocannabinoids) and we also consume them in some foods (exocannabinoids). Most of these cannabinoids, including CBD, are not psychoactive – THC being an exception – but they all offer profound benefits. CBD is one of the most well researched non-psychoactive cannabinoids and it has an incredible array of health benefits, with evidence showing that has profound anti-inflammatory and immune modulating effects and can help with painanxietydepressioncertain cancers, and even heart health.

Let that sink in for a moment. The opioid epidemic is killing an astonishing number of Americans every year; rates of anxiety and depression are reaching new highs, particularly among young people; heart disease is the leading cause of death for adults in the US. CBD has been found to help with all of these conditions, but instead of working to make this compound more widely available as a supplement, which is the way it should be sold according to the Dietary Supplement and Health Education Act of 1994 (DSHEA), the FDA wants to stop all supplement sales of CBD. The FDA’s justification is the protection of the profits of one pharmaceutical company that has a CBD drug that will cost patients a stunning $32,500 per year. It will also mean citizens who have been benefiting from low-cost health support from CBD supplements since they became widely available a few years ago will have no further access to the supplements they have relied on. There is something deeply wrong with this picture.

How did we get here? For starters, the FDA says that CBD can’t be a supplement because it has approved a drug version of CBD called Epidiolex that is used to treat two rare forms of epileptic seizure, Lennox-Gastaut syndrome (LGS) or Dravet syndrome, in children over 2 years. This ability for FDA to rule in favor of drug companies has to do with the FDA back-channel that we’ve written about many times before. In short, if a substance is studied as a drug (i.e. a drug company has made an Investigational New Drug application) before there is evidence it was sold as a supplement (i.e. evidenced by a supplement company’s New Dietary Ingredient notification), then the drug company can ask the FDA to ban the supplement form of that compound.

Yet, as pressure mounts from Congress and a variety of stakeholders to make CBD more widely available, the FDA has been reviewing scientific information on CBD. Earlier this year, the agency released a statement explaining that the “existing regulatory framework” for foods and supplements is not appropriate for CBD and that a new regulatory pathway is needed.

One of the main issues raised by the FDA is that of safety. The agency claims that CBD presents various safety concerns, specifically the potential for harm to the liver and the reproductive system and concerns for vulnerable populations such as children and pregnant women.

These views are articulated in a review article authored in part by FDA staff. To support the assertion that CBD can pose threats to the male reproductive system, the authors cite a 1981 animal study in which monkeys were administered 30, 100, or 300 milligrams per kilogram of body weight per day (mg per kg bw/day) of CBD orally. But consider that 300 mg per kg bw/day for a human weighing 154 pounds would be 21,000 mg, or 21g, of CBD—far, far more than anyone would ever take as a supplement!

This is emblematic of a larger problem we’ve discussed before: the deeply flawed risk assessment models used by federal bureaucrats to prevent us from utilizing natural medicines to stay healthy. These types of models have been used by European regulators to set absurd limits on supplement dosages (known as tolerable upper limits, or ULs). ANH’s founder and Executive and Scientific Director, Robert Verkerk, PhD, has published several papers critiquing this approach that was originally developed by the Institute of Medicine (now the National Academy of Medicine), pointing to a fundamental flaw: in trying to restrict vitamin or other micronutrient dosages in this way, regulators completely ignore the fact that risks vary greatly depending on the form and dose of a nutrient used, and for most populations you’ll find overlap in the doses that cause health benefits for the majority and risks for a few. So if you then create a law that aims to eliminate a potential risk for everyone, you actually deprive the vast majority access to the micronutrient and all the benefits it offers.

Bringing it back to CBD: the fact that the FDA is, in part, using a decades-old animal study in which an absurdly high CBD dose was used to demonstrate that CBD has safety concerns once again demonstrates that the federal approach to assessing risk and benefit is fundamentally broken. It’s based on a defunct toxicological model that should have no place in modern day food or supplement law-making. The agency is also not giving proper weight to the incredibly favorable safety record of CBD used as a supplement or the multitude of benefits we can get from using CBD as a supplement. Instead, the FDA has chosen to focus on old evidence of harm that was only found when absurdly high doses were taken experimentally. To us, it seems like the agency is simply grasping at any information it can to demonstrate harm so it can justify its proposed ban on CBD supplements. The driver? Nothing less than preventing competition for the pharmaceutical drug version of CBD, given its the drug companies that are the FDA’s principal paymasters.

And, indeed, the FDA’s view on CBD’s safety is not supported by experts in the industry and elsewhere. A 2020 meta-analysis looked at human trials to assess CBD efficacy and safety. The authors concluded that most studies reported no adverse events with acute administration of CBD and mild to moderate effects with chronic administration, with the most common side effects being tiredness, diarrhea and changes of appetite/weight. Again, these side effects must be weighed against the benefits of CBD use for combatting opioid misuse, heart disease, anxiety, and depression. Harvard Health Publishing, the publication of the Harvard Medical School, states simply that, for adults, “CBD appears to be very safe.”

We cannot allow the FDA to cater to the drug industry at the expense of public health.

Action Alert! Write to Congress in support of bills that allow the legal sale of CBD in supplements. Please send your message immediately.

The FDA has said that they will not be allowing CBD to be in food or supplements, explaining that the “existing regulatory framework” for foods and supplements are not appropriate for CBD. The agency denied three Citizens Petitions requesting the agency issue a regulation that would allow CBD to be sold as a supplement. Clearly the FDA is more interested in protecting Big Pharma profits than with promoting consumer access to a product that can benefit their health. We need Congress to take the issue out of the FDA’s hands to create a legal pathway for CBD supplements.

Write to Congress and tell them to support the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2023 and the Hemp Access and Consumer Safety Act to protect access to CBD supplements.

Sign the Petition Here

_________________

**Comment**

The FDA wants patients between a rock and a hard place.  On one hand they state extended antibiotics are not to be used for Lyme/MSIDS because they are unsafe, and then they also want to remove important supplements that help us, but when the agency is alerted to the fact doctors have never witnessed so many “vaccine”-related injuries and VAERS reports are higher than any other vaccine in its history, after the mRNA gene therapy injections……crickets.

Something doesn’t smell right.

If the FDA had their way we’d just all die already.

For more:

The FDA has a long & sordid history of attempting to ban anything it views as competition to its lucrative drugs & vaccines due to its vested interests with Big Pharma.